



Clinical trial results:

A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals' HPV vaccine in healthy Chinese female subjects who received three doses of the vaccine in the HPV-058 study

Summary

EudraCT number	2017-000255-50
Trial protocol	Outside EU/EEA
Global end of trial date	29 June 2018

Results information

Result version number	v2 (current)
This version publication date	23 December 2020
First version publication date	19 May 2019
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Minor changes implemented in the full study results to account for consistency with other registries.

Trial information

Trial identification

Sponsor protocol code	207347
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03355820
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 December 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 June 2018
Global end of trial reached?	Yes
Global end of trial date	29 June 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the immune response against HPV types 16 and 18 [as determined by Enzyme Linked Immunosorbent Assay (ELISA)] 7 to 8 years after completion of the vaccination schedule in the HPV-058 study.

Protection of trial subjects:

All subjects were followed up for reporting of serious adverse events (SAEs) that were related to study participation (i.e. protocol-mandated procedures) or to a concurrent GSK medication/vaccine. Data were collected and recorded from the time the subject consented to participate in the study until the end of participation in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 February 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	China: 227
Worldwide total number of subjects	227
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	7
Adults (18-64 years)	220
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study was conducted at a single center in China.

Pre-assignment

Screening details:

228 subjects were included in the Enrolled Set, 1 subject was excluded from all statistical analyses, thus 227 subjects formed the Exposed Set.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	HPV Group
-----------	-----------

Arm description:

Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) study.

Arm type	Experimental
Investigational medicinal product name	Cervarix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

In order to assess the persistence of immune responses seven to eight years after the last vaccine dose in the primary study, a blood sample was taken from all the subjects at Day 1 in the present study. No vaccine was administered in this extension study. Subjects received 3 doses of the Cervarix vaccine administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the primary study HPV-058 (NCT00996125).

Number of subjects in period 1	HPV Group
Started	227
Completed	227

Baseline characteristics

Reporting groups

Reporting group title	HPV Group
-----------------------	-----------

Reporting group description:

Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) study.

Reporting group values	HPV Group	Total	
Number of subjects	227	227	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	7	7	
Adults (18-64 years)	220	220	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous			
Units: Years			
arithmetic mean	21.6		
standard deviation	± 2.3	-	
Sex: Female, Male			
Units: Subjects			
Female	227	227	
Male	0	0	
Race/Ethnicity, Customized			
Units: Subjects			
Asian - East Asian Heritage	227	227	

End points

End points reporting groups

Reporting group title	HPV Group
Reporting group description: Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) study.	

Primary: Number of seropositive subjects for anti-HPV-16 antibodies at Day 1 in HPV-093 (NCT03355820) study

End point title	Number of seropositive subjects for anti-HPV-16 antibodies at Day 1 in HPV-093 (NCT03355820) study ^[1]
End point description: A seropositive subject is defined as a subject whose antibody concentration is equal to or above the cut-off value of 19 Enzyme Linked Immunosorbent Assay units per milliliter (EL.U/mL).	
End point type	Primary
End point timeframe: At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: Subjects				
Anti-HPV-16	223			

Statistical analyses

No statistical analyses for this end point

Primary: Number of seropositive subjects for anti-HPV-18 antibodies at Day 1 in HPV-093 (NCT03355820) study

End point title	Number of seropositive subjects for anti-HPV-18 antibodies at Day 1 in HPV-093 (NCT03355820) study ^[2]
End point description: A seropositive subject is defined as a subject whose antibody concentration is equal to or above the cut-off value of 18 EL.U/mL.	
End point type	Primary
End point timeframe: At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study)	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: Subjects				
Anti-HPV-18	223			

Statistical analyses

No statistical analyses for this end point

Primary: Anti-HPV-16 antibody concentrations at Day 1 in HPV-093 (NCT03355820) study

End point title	Anti-HPV-16 antibody concentrations at Day 1 in HPV-093 (NCT03355820) study ^[3]
-----------------	--

End point description:

Anti-HPV-16 antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in EL.U/mL.

End point type	Primary
----------------	---------

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-HPV-16	1236.3 (1121.8 to 1362.4)			

Statistical analyses

No statistical analyses for this end point

Primary: Anti-HPV-18 antibody concentrations at Day 1 in HPV-093 (NCT03355820) study

End point title	Anti-HPV-18 antibody concentrations at Day 1 in HPV-093
-----------------	---

End point description:

Anti-HPV-18 antibody concentrations are presented as GMCs, expressed in EL.U/mL.

End point type

Primary

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
Anti-HPV-18	535.6 (478.6 to 599.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-HPV-16 antibodies at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies

End point title	Number of seropositive subjects for anti-HPV-16 antibodies at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies
-----------------	---

End point description:

A seropositive subject is defined as a subject whose antibody concentration is equal to or above the cut-off value of 19 EL.U/mL. The number of seropositive subjects at Day 1 in the present study was compared with the number of seropositive subjects from the immunogenicity subset in HPV-039 (NCT00779766) study at Year 6. Data corresponding to Day 1 time point of the present study can also be found in the primary outcome measure. Data at Year 6 in subjects from the immunogenicity subset in HPV-039 study can be found in the respective NCT record NCT00779766 (please refer to Outcome measure 38, Row "≥19 EL.U/mL, sero-, [Month 72]" and Row "≥19 EL.U/mL, sero+, [Month 72]").

End point type

Secondary

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study) and at Year 6 in HPV-039 (NCT00779766) study

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: Subjects				
HPV-093, Day 1	223			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of seropositive subjects for anti-HPV-18 antibodies at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies

End point title	Number of seropositive subjects for anti-HPV-18 antibodies at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies
-----------------	---

End point description:

A seropositive subject is defined as a subject whose antibody concentration is equal to or above the cut-off value of 18 EL.U/mL. The number of seropositive subjects at Day 1 in the present study was compared with the number of seropositive subjects from the immunogenicity subset in HPV-039 (NCT00779766) study at Year 6. Data corresponding to Day 1 time point of the present study can also be found in the primary outcome measure. Data at Year 6 in subjects from the immunogenicity subset in HPV-039 study can be found in the respective NCT record NCT00779766 (please refer to Outcome measure 39, Row "≥ 18 EL.U/mL, sero- [Month 72]" and Row "≥ 18 EL.U/mL, sero+ [Month 72]").

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study) and at Year 6 in HPV-039 (NCT00779766) study

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: Subjects				
HPV-093, Day 1	223			

Statistical analyses

No statistical analyses for this end point

Secondary: Concentration of antibodies against HPV-16 at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies

End point title	Concentration of antibodies against HPV-16 at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies
-----------------	---

End point description:

Anti-HPV-16 antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in EL.U/mL. Anti-HPV-16 antibody concentrations at Day 1 in the present study were compared with the anti-HPV-16 antibody concentrations obtained as per the analysis performed on the immunogenicity subset in HPV-039 (NCT00779766) study at Year 6. Data corresponding to Day 1 time point of the present study can also be found in the primary outcome measure. Data at Year 6 in subjects from the immunogenicity subset in HPV-039 study can be found in the respective NCT record NCT00779766 (please refer to Outcome measure 40, Row "HPV-16, sero-, [Month 72]" and Row "HPV-

16, sero+, [Month 72]").

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study) and at Year 6 in HPV-039 (NCT00779766) study

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
HPV-093, Day 1	1236.3 (1121.8 to 1362.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Concentration of antibodies against HPV-18 at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies

End point title	Concentration of antibodies against HPV-18 at Day 1 in HPV-093 (NCT03355820) and at Year 6 in HPV-039 (NCT00779766) studies
-----------------	---

End point description:

Anti-HPV-18 antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in EL.U/mL. Anti-HPV-18 antibody concentrations at Day 1 in the present study were compared with the anti-HPV-18 antibody concentrations obtained as per the analysis performed on the immunogenicity subset in HPV-039 (NCT00779766) study at Year 6. Data corresponding to Day 1 time point of the present study can also be found in the primary outcome measure. Data at Year 6 in subjects from the immunogenicity subset in HPV-039 study can be found in the respective NCT record NCT00779766 (please refer to Outcome measure 40, Row "HPV-18, sero-, [Month 72]" and Row "HPV-18, sero+, [Month 72]").

End point type	Secondary
----------------	-----------

End point timeframe:

At Day 1 in HPV-093 (NCT03355820) study (i.e. 7 to 8 years after completion of the vaccination schedule in HPV-058 [NCT00996125] study) and at Year 6 in HPV-039 (NCT00779766) study

End point values	HPV Group			
Subject group type	Reporting group			
Number of subjects analysed	223			
Units: EL.U/mL				
geometric mean (confidence interval 95%)				
HPV-093, Day 1	535.6 (478.6 to 599.4)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

At Day 1

Adverse event reporting additional description:

There were no adverse events (AEs) data collected during the entire study period (i.e. at Day 1). Only SAEs related to study procedures or concomitant GSK medications/vaccines and events with a fatal outcome were recorded and collected during the entire study period (i.e. at Day 1).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

Reporting groups

Reporting group title	HPV Group
-----------------------	-----------

Reporting group description:

Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) study.

Serious adverse events	HPV Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 227 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	HPV Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 227 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: There were no adverse events (AEs) data collected during the entire study period (i.e. at Day 1). Only SAEs related to study procedures or concomitant GSK medications/vaccines and events with a fatal outcome were recorded and collected during the entire study period (i.e. at Day 1).

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported